IMMP
IMMUTEP Narrows Efti Strategy After TACTI-004 Failure, Blames Manufacturing
Immutep traces the failed TACTI-004 trial to structural differences in efti made at 2,000 L scale and refocuses on HNSCC with CPS < 1 and neoadjuvant sarcoma.
IMMP
Market-moving news on Immutep (NASDAQ: IMMP): filings, earnings, deals and other events, from REDFILED.